Cipla (CIPLA.NS)

Quick facts

Marketed products

• Tasigna · Oncology · revenue 400
  Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cipla portfolio CI brief
• Cipla pipeline updates RSS